Status
Conditions
Treatments
About
Dynamic multiomics detection of plasma derived exosomes to explore the efficacy and mechanism of anti-HER2, immunotherapy and anti-CLDN18.2 of gastrointestinal cancer.
Full description
The investigators will recruit 500 advancer/late-stage gastrointestinal cancer patients.Blood and tumor tissue will be collected at treatment baseline, every time point response till disease progression. All samples will be processed by exosomes proteome detection to explore the efficacy and mechanism of anti-HER2, immunotherapy and anti-CLDN18.2 of gastrointestinal cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Having signed informed consent
Exclusion criteria
Previous systemic therapy for metastatic GI cancer
500 participants in 3 patient groups
Loading...
Central trial contact
Zhang Cheng, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal